Liposomes are microscopic vesicles consisting of multiple concentric lipid bilayers formed when an aqueous solution is added to a dried lipid film. Since their initial description by Bangham et al. (5) , several types of liposomes have been characterized (41) . Multilamellar liposomes or multilamellar vesicles have been extensively used as carriers of antineoplastic and antimicrobial drugs. These multilamellar vesicles have two parts: an extensive lipid compartment that embodies the multiple lipid layers and an aqueous compartment that consists of the spaces between the layers.
As with most drug carriers, liposomes have been extensively used in an attempt to improve the therapeutic index of known active drugs, such as Adriamycin (14) . In those studies, the major reduction observed in the target-organ toxicity of the drugs was probably related to a modification in drug distribution. Liposomes are preferentially taken up by organs rich in cells from the reticuloendothelial system. In mice (30) and humans (25) , liposomes have been shown to localize in the liver, spleen, lung, and bone marrow.
The biologic and pharmacologic attributes of liposomes have been exploited by several investigators for the delivery of antimicrobial agents (Table 1) . Liposome type, size, lipid composition, membrane fluidity, stability and charge, and ease of preparation are factors that must be considered when designing liposomal carriers. Multilamellar vesicles with their large lipid compartment offer an advantage for the incorporation of hydrophobic drugs; in contrast, reverse evaporation vesicles are a better choice for the incorporation of hydrophilic compounds. Usually, naturally occurring, biodegradable, and nontoxic phospholipids, such as lecithin, phosphatidyl serine, and phosphatidyl glycerol, are selected. The fluidity and charge of the liposomal membranes can be altered to facilitate specific objectives, such as in the case of macrophage targeting, in which negatively charged liposomes with more fluid membranes are preferentially phagocytosed. The incorporation of sterols (ergosterol and cholesterol) increases the rigidity and stability of liposomes. However, in the case of amphotericin B (AmpB) the use of sterol-containing liposomes results in decreased antifungal activity. This latter observation is probably related to tight drug-sterol binding which impedes the exchange of the drug with fungal membranes. AmpB AmpB, a heptaene antibiotic, is a highly effective but toxic antifungal drug whose activity is related to its capacity to interact with lipids in biologic membranes (3, 17) . The high hydrophobicity of AmpB makes it a good candidate for liposomal incorporation. Liposome-incorporated AmpB (LAmpB) has been studied in a variety of experimental infections. Early work by New et al. (36) demonstrated that L-AmpB was less toxic and more active against experimental leishmaniasis than the free drug (Fungizone). They reported that the lipid composition influenced the toxicity of liposomes, and they observed a decreased toxicity with liposomes composed of sterols, hydrogenated lecithins, or both. Similar results were observed by Graybill et al. (16) against experimental cryptococcosis and by Taylor et al. (42) against experimental histoplasmosis. In both cases, the incorporation of AmpB in liposomes resulted in lower toxicity and at least equal therapeutic efficacy. L-AmpB was also shown to be far less toxic than AmpB but similarly active against experimental candidiasis ( Fig. 1 ; 24, 26, 28) . In early studies, the toxicity of AmpB was reduced 10-to 20-fold by encapsulation, thus allowing the use of higher single doses in therapeutic experiments. Furthermore, LAmpB proved to be superior to AmpB in the treatment and prophylaxis of experimental candidiasis in neutropenic mice (24) .
We also observed that the lipid composition played a major role in L-AmpB activity. L-AmpB preparations composed of phospholipids alone were shown to be more effective than those containing ergosterol or cholesterol (27) . A possible explanation for these findings was that the sterolcontaining L-AmpB preparations combined AmpB more tightly, reducing the potential for drug interaction with fungal membranes.
Clinical studies. Systemic fungal infections are a frequent complication in patients with hematologic malignancies and in immunocompromised patients (10, 15) . Although in these patients AmpB is the drug of choice, its usefulness is often limited by its associated toxicity. Maksymiuk et al. (31) observed that of 93 patients with systemic candidiasis, none with persistent neutropenia, including 25 patients who were treated with antifungal therapy, survived the infection. Of the patients with systemic candidiasis who recovered from neutropenia and were treated with antifungal agents, 38% were cured.
Nineteen patients with systemic fungal infections complicating their hematologic malignancies have been treated (22a, 23) . Of these, 18 had been previously treated with antifungal agents, including AmpB, and 1 patient had a bona fide history of anaphylactic reaction to AmpB. All had histologic and cultural evidence of progressive fungal infection at the start of therapy with L-AmpB. Nine patients were cured, six had partial responses, and four did not respond to treatment (Table 2) . Nine patients were neutropenic throughout treatment; of these, one was cured, four had partial responses, and four did not respond to therapy. Responses were observed in patients with pulmonary, sinus, hepatosplenic, and renal infections. Fever and chills were seen infrequently and responded well to meperidine or diphenhydramine. No evidence of chronic renal or central nervous system toxicity has been observed in patients with ANTIMICROB. AGENTS CHEMOTHER. follow-up periods greater than 1 year. In none of the nine patients cured who received additional chemotherapy for their leukemia (of these patients, two had bone marrow transplantation) was there evidence of recurrence of the fungal infection. Pharmacologic considerations. The mechanisms involved in the enhanced therapeutic index observed with L-AmpB are not well understood, but tissue localization may play a role. We observed that when AmpB was given in liposomes, higher concentrations were found in the liver, spleen, lung, and kidney tissue of mice infected with Candida albicans (30) . However, tissue localization alone may not be the explanation, since AmpB concentrations exceeding 160 ,ug/g of tissue (liver and spleen) were noted in patients with hepatic candidiasis failing to respond to AmpB (9) .
This observation raises the possibility that L-AmpB may be delivered to the infected sites via either capillary leakage or secondary transport by phagocytes. In vitro, it has been shown that L-AmpB fungicidal activity was maintained, although its toxicity to erythrocytes was abrogated (33). However, the presence of serum reduces the toxicity of AmpB; therefore, the conditions present in the biologic microenvironment were not accurately reflected in these experiments. We also observed that the suppressive effect of AmpB on macrophages (32) was also nullified by AmpB incorporation in liposomes (34) . Thus, a preponderant exchange of AmpB from sterol-free liposomes to ergosterolcontaining fungal membranes may also be a factor.
ANTIMONIAL DRUGS An excellent example of the use of liposomes to carry antimicrobial agents was provided by the studies of Alving et al. (1, 2) in the treatment of experimental leishmaniasis. Leishmanias are intracellular parasites of phagocytic cells of the reticuloendothelial system, offering a natural target for liposomal delivery. These investigators showed that liposome-incorporated antimicrobial agents and 8-aminoquinolines were far superior to the free drugs against this parasite. CEPHALOTHIN Liposome-incorporated cephalothin has been shown to be effective in the treatment of other facultative intracellular bacteria. Desiderio and Campbell (11, 12) showed that liposome-encapsulated cephalothin was more effective than the free drug in the treatment of experimental murine salmonellosis. Mice treated with the liposomal form of the drug had a reduced number of salmonellae in the liver and spleen. PRIMAQUINE Liposome encapsulation of primaquine phosphate has been demonstrated to reduce the acute toxicity related to the drug while allowing it to maintain its efficacy against murine malaria (39, 40) . Although drug targetting was not the major objective in these experiments, its therapeutic index was enhanced. Primaquine phosphate is toxic mainly to the lungs, heart, kidneys, and brain; by incorporation in liposomes, its distribution is radically modified.
IMMUNOMODULATORS
Macrophages are a major component of the defenses of a host against microbial diseases. Several synthetic and biologic products can render macrophages activated to destroy microorganisms and neoplastic cells. Liposome-incorporated macrophage activators have been shown to be more effective than free agents in the activation of macrophages for antitumor activity (29) . A similar rationale was used to treat herpes (18) (19) (20) , hepatitis (22) , and fungal (13) 
